Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced that they are a recipient of a Phase II SBIR grant from the National Institutes of Health (NIH) for $2.3 million.

Rockville, MD. Rise Therapeutics announced today it was awarded a $2 million, multi-year grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program through the National Institute of Dental and Craniofacial Research (NIDCR). Grant funds will be used to develop a novel, immunologically enhanced probiotic-based therapeutic for the treatment of Sjögren’s syndrome (SS).

Virtici, LLC today announced the launch of an online resource database for biomedical entrepreneurs: http://bioentrepreneurresources.com. This database was developed in collaboration with the DRIVEN Accelerator Hub, a parallel NIH-funded consortium led by Celdara Medical including 10 of the leading research institutions in the Northeast region (NH, VT, ME, DE, and RI).

Diabetes is a disease of high blood sugar. Diabetic patients also can experience extremely low blood sugar, or hypoglycemia, after fasting, exercising or too large a dose of insulin. If untreated, severe hypoglycemia can lead to coma or even death.

Virtici announced today that it has received a three-year, $3.5 million award from the National Institutes of Health (NIH) to support an Institutional Development Award (IDeA) Center of Biomedical Research Excellence.

Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced it has closed on $1.8M in Series A financing to support the launch of its new microbiome platform technology.